Premium
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes
Author(s) -
Linnebjerg H.,
Kothare P. A.,
Skrivanek Z.,
Peña A.,
Atkins M.,
Ernest C. S.,
Trautmann M. E.
Publication year - 2006
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2006.01800.x
Subject(s) - exenatide , postprandial , medicine , placebo , type 2 diabetes , crossover study , endocrinology , insulin , diabetes mellitus , hypoglycemia , meal , gastroenterology , alternative medicine , pathology
Aims Exenatide is an incretin mimetic whose effect on glycaemic control in patients with Type 2 diabetes is currently under investigation. This study assessed the effect of injection time relative to a standardized meal on postprandial pharmacodynamics of exenatide in patients with Type 2 diabetes. Methods Eighteen patients participated in this single‐centre, open‐label, placebo‐controlled, randomized, six‐way crossover study. Patients received subcutaneous injections of either placebo (−15 min) or 10 µg of exenatide at −60, −15, 0, +30 or +60 min relative to a standardized breakfast meal on six consecutive days. Serial blood samples were assayed for plasma glucose and insulin concentrations. Results For all exenatide treatments, incremental postprandial glucose area under the postprandial plasma glucose curve from zero to 6 h (AUC 0−6 h ) was significantly reduced compared with placebo. When exenatide was administered before (−60, −15 min) or with the meal (0 min), peak postprandial glucose concentrations were significantly decreased ( P < 0.0001 for all treatments) compared with placebo. Post‐meal exenatide administration (+30, P < 0.05; +60 min, P = 0.21) resulted in smaller peak glucose reductions and in some patients transient low plasma glucose concentrations were reported. Peak plasma insulin concentrations in the pre‐meal treatments were significantly lower than placebo ( P < 0.05 for all treatments), while post‐meal dosing groups exhibited a trend towards higher insulin peaks compared with placebo. The most common adverse events related to exenatide were headache, nausea, dyspepsia and vomiting, and were generally of mild‐to‐moderate intensity. Conclusions In this study, all exenatide treatments demonstrated reductions in postprandial plasma glucose excursions compared with placebo. Pre‐meal and with meal administration of exenatide produced greater reduction of postprandial glucose excursions compared with post‐meal administration. These data support flexible dosing of exenatide at any time within 60 min before a meal.